CSE antibodies are widely used in:
Breast Cancer: CSE is upregulated in triple-negative breast cancer (TNBC) and ER+ tumors. Antibody-based studies show CSE promotes proliferation, migration, and tamoxifen resistance via H₂S-mediated pathways .
Colorectal Cancer: CSE deficiency in bone marrow-derived cells accelerates colitis-associated carcinogenesis by altering IL-10/IL-6 balance .
Inhibitor Development: The CSE inhibitor I194496 reduces TNBC growth by suppressing PI3K/Akt and Ras/ERK pathways (IC₅₀ = 0.79 mM for CSE) .
Biomarker Potential: Anti-CSE antibodies in serum correlate with neurocysticercosis treatment response (66.6% sensitivity pre-treatment) .
Neurocysticercosis: Anti-CSE antibodies in serum decline post-albendazole therapy, showing utility in monitoring treatment efficacy :
| Antigen | Pre-Treatment Positivity | 3–6 Months Post-Treatment | 12 Months Post-Treatment |
|---|---|---|---|
| CSE | 42.4% | 15.1% | 15.1% |
| ES | 66.6% | 6% | 0% |
Anti-CSE antibodies are linked to celiac disease (71% sensitivity, 99% specificity) and dissipate post-gluten-free diet .